Health Canada authorizes functional claims that the probiotic strain DDS-1® “helps alleviate perceived stress and improve irritable bowel syndrome-related quality of life in adolescents and adults”
The ‘gut-brain axis’ has become one of the most cutting-edge areas of research over the past few years, diving into how the fascinating interplay between the brain, gut and microbiome can impact physical and digestive issues, as well as mental well-being. It is well-known, for example, that people with irritable bowel syndrome (IBS) frequently report feeling sad, embarrassed and self-conscious, which impacts their quality of life and could even limit participation in social activities (1).
Chr. Hansen’s probiotic strain L. acidophilus, DDS-1® is already authorized by Health Canada to help improve abdominal pain severity and symptomology in IBS in adolescents and adults. Now the existing Natural Health Product (NPH) license for the DDS-1® strain in Canada has been amended to include the following gut-brain axis claims:
- Helps alleviate perceived stress in adolescents and adults with irritable bowel syndrome
- Helps to improve irritable bowel syndrome-related quality of life in adolescents and adults
- Helps alleviate perceived stress in conjunction with improving abdominal pain in adolescents and adults with irritable bowel syndrome
- Helps normalize stool consistency of those with irritable bowel syndrome in adolescents and adults.
Quality stamp of the science behind
“We are excited that one of our probiotic strains has received official Canadian health claims relating to the gut-brain axis, putting a quality stamp on the science behind our product and adding credibility to our offering in this emerging field,”
says Niklas Larsson, PhD, Head of Scientific Affairs, Chr. Hansen Human Health.
“It will assist consumers in making informed health choices when selecting probiotics and reinforce their confidence that the products are effective, safe and of high quality. Officially registered health claims will drive increased interest in our clinically documented probiotics and their potential benefit in general, both in Canada and other markets,”
concludes Linda Neckmar, SVP, Chr. Hansen Human Health.